General Proximity

The next generation of induced-proximity medicines.

Y CombinatorWinter 2020ActiveHealthcareDrug Discovery and DeliveryBiotechDrug discovery

What they do

Problem

Many diseases lack effective treatments because existing drugs cannot precisely modulate disease-causing proteins and pathways.

Solution

The company develops induced-proximity medicines that bring specific proteins into close proximity to control or alter their function for therapeutic effect.

Who it's for

Pharmaceutical and biotech companies and clinicians/researchers developing and delivering new therapeutics.

Founders

Armand Cognetta

Founder

Armand completed his PhD in Chemical Biology at the Scripps Research Institute under the supervision of Dr. Benjamin F. Cravatt. There he co-authored 19 scientific publications in prestigious journals such as Cell, Nature, and Science, as well as multiple patents, including a portion of the foundational IP for Abide Therapeutics (acq. Lundbeck) and Vividion Therapeutics (acq. Bayer). Prior to founding GP he was an early employee at the Flagship Pioneering start-up Inzen Tx (now Sonata).

LinkedIn · X